Efficacy and Safety of Corticosteroids’ Administration for Pulmonary Immaturity in Anticipated Preterm Delivery

Author(s): Themistoklis Dagklis, Ioannis Tsakiridis, Georgios Papazisis, Apostolos Athanasiadis*

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 36 , 2021

Become EABM
Become Reviewer
Call for Editor


Preterm delivery represents the major cause of neonatal morbidity and mortality. Respiratory morbidity is the primary cause of early neonatal mortality and disability. The administration of antenatal corticosteroids, in cases of imminent preterm delivery, can enhance fetal lung maturation and reduce the incidence of respiratory distress syndrome, leading to improved neonatal outcomes. The scope of this narrative review was to synthesize available evidence on the efficacy and safety of corticosteroids' administration during antenatal period, in cases of anticipated preterm delivery. Hence, for those cases, a single course of antenatal corticosteroids from 24 up to 34 gestational weeks should be offered. Betamethasone and dexamethasone are the most widely used drugs, with similar effectiveness and a recommended dosage of 24mg in divided doses, over a 24- hour period. However, there is an ongoing debate regarding the gestational age of administration. Some obstetric societies recommend their administration even at 22 weeks of gestation. Conflicting is also their usefulness in late preterm cases (between 34 and 37 weeks) or in cases of elective cesarean delivery at term. The use of repeated courses of corticosteroids may be considered in specific cases, however, concerns on the long-term outcomes of repeated courses beyond 34 gestational weeks have been raised.

Keywords: Corticosteroids, pregnancy, fetal lung maturation, preterm delivery, prematurity, timing, course, outcome.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 06 December, 2020
Page: [3754 - 3761]
Pages: 8
DOI: 10.2174/1381612826666201207102910
Price: $65

Article Metrics

PDF: 290